MEMPHASYS LIMITED. — Capital/Financing Update 2014

Mar 2, 2014

==> picture [196 x 96] intentionally omitted <==

Loan Facilities

Sydney, Australia 3[rd] March 2014

NuSep Holdings Ltd (ASX:NSP) is pleased to announce that PriIME Biologics Pte Ltd, one of its subsidiaries, has entered into a loan facility for a total of A$825,000 and S$120,000 and NuSep Holdings Limited has entered into a loan facility for A$500,000.

The first loan facility is of a short term nature and has been provided to PrIME Biologics Pte Ltd by a consortium of lenders including Mr. John Manusu and Dr. Hari Nair, both directors of the borrower and former directors of NuSep Holdings Limited. The other two lenders are unrelated parties to the borrower and NuSep Holdings Limited.

The first loan facility is for an amount of A$825,000 and S$120,000 and has been provided for a term of no more than 12 months and carries an interest rate of 10 percent per annum. The loan is to be used for working capital purposes and is secured via a mortgage over certain plant and equipment owned by the borrower.

The first loan facility also anticipates the issue of one percent of shares in PrIME Biologics Pte Ltd for every S$1,000,000 advanced, subject to the approval of NuSep Holdings Limited and its shareholders, if required. The loan facility also anticipates that if NuSep Holdings Limited is subject to a takeover offer then any amounts outstanding under the facility will be converted into fully paid ordinary shares of NuSep Holdings Limited at a price equal to 85% of the 20 day Volume Weighted Average Price of the shares immediately prior to the announcement of the takeover bid.

It is expected that the first loan facility will be re-paid with funds received from the first tranche of an anticipated investment by Xeraya Capital Labuan Ltd, details of which have already been announced to the market.

The second loan facility is for an amount of A$500,000. It is of a long term nature and has been provided to NuSep Holdings Limited by Mr. Andrew Goodall, a director of both the borrower and PrIME Biologics Pte Ltd.

The second loan facility has been provided for a fixed term expiring on 15[th] January 2016 and carries an interest rate of 14 percent per annum. The loan is to be used for working capital purposes and is secured via a charge over the assets of NuSep Holdings Limited excluding the fixed assets of PrIME Biologics Pte Ltd.

The second loan facility anticipates, subject to shareholder approval, the issue of 750,000 unlisted share options in NuSep Holdings Limited to Mr. Goodall at an exercise price of 11.2 cents ($0.112), and expiring 20[th] January 2016.

NuSep Holdings Ltd 30 Richmond Rd Homebush NSW 2140

Contact Details Email info@nusep.com Telephone +61 2 8415 7300 Web www.nusep.com Facsimile +61 2 8415 7399 ABN 33 120 047 556

Postal Address P.O. Box 2202 Homebush West NSW 2140

– 2 –

For further information please contact:

Alison Coutts Executive Chairman +61 2 8415 7300 alison.coutts@nusep.com

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques based on its PrIME[1] technology. The PrIME technology has produced a number of world firsts including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

==> picture [12 x 17] intentionally omitted <==

• Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

==> picture [12 x 17] intentionally omitted <==

• Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.

==> picture [12 x 17] intentionally omitted <==

• Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin .

For more information about NuSep please visit the company’s website www.NuSep.com

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable therapeutic plasma manufacturing process based on NuSep’s PrIME Technology. PrIME Biologics process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause ‘Mad Cow Disease’. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many Asian countries.

1 PrIME stands for Pr eparative I solation by M embrane E lectrophoresis

– 3 –